NEWS OF THE WEEK STRUCTURAL
BIOLOGY
TRACING SARS'S JUMP TO HUMANS Protein bound to its receptor reveals how virus adapted to human host
P
UBLIC HEALTH EXPERTS
hope that surveillance of animal coronaviruses for those poised to "jump" to humans could help prevent outbreaks of deadly diseases like severe acute respiratory syndrome (SARS). A new structural biology study has pinpointed what scientists should look for when patrolling for animal viruses that could cause another SARS outbreak. The deadly human coronavirus behind the 2002-03 SARS epidemic—during which nearly 10% of the roughly 8,000 people infected died—originated in animals such as civet cats. Genetic sequencing has shown that the animal and human viruses differ by just a handful of mutations in a few viral genes. Some mutations are located on a spike-shaped protein that the coronavirus uses to bind to its host receptor, a zinc protease known as ACE2. A team led by structural biologist Stephen C. Harrison of Harvard Medical School has now revealed the structure of a piece of the human coronavirus spike protein bound to human ACE2 (Science 2005,309,1864). "Understanding the structure of this complex will help us understand what these mutations in the spike protein mean in terms of infectivity," says Harrison, whose team includes his Harvard colleagues Fang Li, Wenhui Li, and Michael Farzan. In the complex, the spike protein cradles ACE2. Smack in the middle of the interface between the two proteins is a pair of amino acids that Farzan's lab had previously fingered as being most critical for the virus's jump from aniWWW.CEN-0NLINE.ORG
mals to humans. These two amino acids differ from those found in the original animal spike protein, Harrison notes. The structure suggests that these mutations allowed animal-to-human transmission by increasing the affinity of the animal coronavirus spike protein for the human ACE2 receptor, he adds. Harrison suggests that the structure might help scientists make predictive guesses about the potential infectivity of newly isolated viruses. He adds that the fragment ofthe spike protein used in the study is a promising starting point for the development of a vaccine against SARS. His team also hopes to devise new SARS antivirals by studying the subsequent conformational changes in the spike protein that help usher the virus into its host
HOST JUMP Two amino acid residues (purple, right and center) that are key to cross-species transmission occur at the interface between the viral spike protein (red and cyan) and its human cell-surface receptor (green).
cell. The Harvard team's search will join others now ongoing. The spike protein is not the only promising target: A Chinese team recently reported the development of a class of peptidomimetic inhibitors of a protease conserved among many coronaviruses (PLoS Biol. 2005, W, e324). They hope that the work will lead to a broad-spectrum drug that could be used tofightnot only the SARS coronavirus but also those that cause conjunctivitis, bronchiolitis, and pneumonia.— AMANDAYARNELL
BIOTECHNOLOGY
Biogen Idee To Cut Jobsp Boost External Focus iogen Idee has announced "a bold reshaping" that aims to reduce annual operating expenses by $200 million to $300 million. The restructuring includes the elimination of 17% of Biogen's workforce, or 650 jobs. The company will take a job-cut-related pretax charge of $30 million to $40 million. Separately, the company announced the departure of Michael Gilman, its executive vice president of research. At the same time, according to a spokesman, the company is "shifting more resources to be externally focused," including collaborations with other firms and academic institutions. Starting in 2006, approximately $200 million annually will be earmarked for business development and external research, up from $50 million this year. The firm says it wilt keep its focus on immunology, neurology, and oncology, remaining
B
"open to both small and large molecules." While Amevive, Biogen's psoriasis drug, is now up for sale, the company says it remains committed to its two $1 billion drugs: the non-Hodgkin's lymphoma drug Rituxan and the multiple sclerosis treatment Avonex. The restructuring is Biogen's second major move following the February withdrawal of the MS drug Tysabri after a patient died from a rare brain infection. In June, the firm sold an underutilized biopharmaceutical plant in Oceanside, Calif., to Genentech for more than $400 million. As part of the new action, Biogen is selling a separate property in Oceanside and its clinical manufacturing facility in San Diego. The company still has manufacturing plants in Research Triangle Park, N.C., and Cambridge, Mass. A plant in Hillerod, Denmark, is under construction and set to open in 2008.-VIVIEN MARX C&EN / SEPTEMBER
19. 2005
9
